Kumkum Saxena

Vice President, Preclinical R&D at Versatope Therapeutics

Speaker

Kumkum Saxena is Vice President and Head of Preclinical R&D at Versatope Therapeutics, an immuno-therapeutic company that harnesses a customized biotechnology platform to deliver immunity. At Versatope, Kumkum is leading the CMC of Versatope’s lead influenza A vaccine candidate, VT-105. Recognized for her expertise in Protein Science, Kumkum possesses an intricate understanding of Protein Structure & Function, complemented by extensive proficiency in large and small-molecule drug discovery. Prior to Versatope, she was Director of Protein Biochemistry and Biophysics at Vertex Pharmaceuticals. Kumkum earned her PhD in Biochemistry from Boston University followed by two intensive Postdoctoral trainings in Cell Biology and Structural Biology at Harvard University.